Time filter

Source Type

Flagler Beach, FL, United States

Palm Beach Atlantic University is a comprehensive interdenominational faith-based university with a core emphasis on character formation by integrating a Christian worldview with the liberal arts and selected professional studies. It is located in West Palm Beach, in the U.S. state of Florida approximately one mile from the Atlantic Ocean on the Intracoastal Waterway. Its purpose is to offer a curriculum of rigorous studies and a program of student activities dedicated to the development of lifetime learning, leadership and service to mankind. The mean SAT is 1270. The student to faculty ratio is 13:1 with 162 faculty. William “Bill” M. B. Fleming, Jr. serves as president of the university. Wikipedia.

Karaoui L.R.,Lebanese American University | El-Lababidi R.,Clinical Pharmacy Services | Chahine E.B.,Palm Beach Atlantic University
American Journal of Health-System Pharmacy | Year: 2013

Purpose. The pharmacology, unique pharmacokinetic - pharmacodynamic profile, and potential future role of oritavancin in combating multidrug-resistant infections are reviewed, with an emphasis on efficacy data from Phase II and III clinical trials. Summary. Oritavancin has been shown to have potent in vitro activity against vancomycin-resistant enterococci (VRE) and staphylococci, methicillin-resistant Staphylococcus aureus (MRSA), and gram-positive anaerobic bacteria. Oritavancin exhibits excellent tissue penetration and concentrates well in macrophages; its prolonged plasma half-life (195.4 hours) and extended in vitro postantibiotic effect (2.4-7.7 hours for MRSA and 1.9-4.3 hours for VRE) might allow once-daily or alternateday dosing. Oritavancin has been shown to have synergistic activity with several antibiotics (e.g., ampicillin, gentamicin, linezolid) against certain infections. In two Phase III clinical trials involving a total of about 1800 patients with complicated skin and skin structure infections (cSSSIs), i.v. oritavancin therapy was shown to have bactericidal activity and a safety profile comparable to those of i.v. vancomycin (plus optional oral cephalexin stepdown therapy) while requiring a significantly shorter duration of therapy; however, the compiled evidence was considered insufficient to justify marketing approval by the Food and Drug Administration, which requested additional safety and efficacy data. Two ongoing Phase III trials evaluating oritavancin for the treatment of acute bacterial SSSIs are expected to be completed in early 2013. During the clinical trials to date, the most commonly reported adverse effects among oritavancin users were headache, nausea, constipation, and phlebitis. Conclusion. Oritavancin is an investigational semisynthetic antibiotic classified as a second-generation lipoglycopeptide, with promising activity against multidrug-resistant gram-positive pathogens. Copyright © 2013, American Society of Health-System Pharmacists, Inc. All rights reserved. Source

Lin S.,Le Moyne College | Zimmer J.C.,Le Moyne College | Lee V.,Palm Beach Atlantic University
Computers and Education | Year: 2013

Combining the Web and mobile technology, podcasting can be an effective tool for mobile and electronic learning, as it provides a learning environment anytime and anywhere. This research investigated how the Unified Theory of Acceptance and Use of Technology (UTAUT) (Venkatesh, Thong, & Xu, 2012) can be applied to study the adoption of podcasting in higher education. Specifically, it examined whether and how user type (teachers or students) may affect differently adoption patterns of podcasting for educational purposes. The key findings include that for intent to adopt podcasting, effort expectancy is more important to students than teachers, while facilitating conditions factors such as copyright clearance and technical support availability are more important to teachers than students. The overall results are expected to contribute to theoretical development and industrial practices in promoting the acceptance of podcasting for educational purposes. © 2013 Elsevier Ltd. All rights reserved. Source

Haines S.L.,Palm Beach Atlantic University | Popovich N.G.,University of Illinois at Chicago
American Journal of Pharmaceutical Education | Year: 2014

A small nonprofit private college with limited resources and a high proportion of junior faculty developed a nontraditional external faculty mentor program in the summer of 2011 in response to the American Association of Colleges of Pharmacy (AACP) faculty survey data regarding the professional development needs of pharmacy faculty members. Experienced faculty members with national reputations from other colleges and schools of pharmacy were hired as consultants to serve as mentors for assigned faculty members. Programgoals were to provide directed, individual mentorship for pharmacy practice and basic science faculty members, expand peer review of faculty teaching prowess, and enhance monthly faculty development programming. The latter was based upon the specific needs assessment of the faculty. Program outcomes reported will include faculty satisfaction (AACP faculty survey data) changes over time, achievement of board certification for clinical faculty members and other credentialing, and other benchmarks, eg, publications, grant funding, service engagement (site development, professional organizations), after the implementation of the nontraditional faculty-mentoring program. Source

Chahine E.B.,Palm Beach Atlantic University | Karaoui L.R.,Lebanese American University | Mansour H.,Lebanese American University
Annals of Pharmacotherapy | Year: 2014

Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosage, and administration of bedaquiline, a novel oral diarylquinoline antimycobacterial agent approved by the Food and Drug Administration for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB). Data Sources: A search of PubMed (January 2004-May 2013) and International Pharmaceutical Abstracts (January 2004-May 2013) using the search terms bedaquiline, diarylquinoline, R207910, and TMC207 was performed. Supplementary sources included proceedings of the Union World Conference on Lung Health. Study Selection and Data Extraction: Preclinical data as well as Phase 1 and 2 studies published in English were evaluated. Data Synthesis: Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase. Clinical trials have been conducted evaluating the use of bedaquiline in combination with a background regimen for the treatment of adults with pulmonary MDR-TB. Bedaquiline has an excellent in vitro activity against Mycobacterium tuberculosis, including multidrug resistant M tuberculosis; however, its side effect profile limits its use against MDR-TB when no other effective regimen can be provided. Bedaquiline carries Black Box warnings for increased risk of unexplained mortality and QT prolongation. Bedaquiline is metabolized via the CYP3A4 isoenzyme and thus interacts with rifamycins and several antiretrovirals. Conclusions: In an era of emerging resistance and given the suboptimal efficacy and toxicity of currently available regimens for MDR-TB, bedaquiline represents a great addition to the existing armamentarium of anti-TB agents particularly in areas of the world where the disease is endemic. © The Author(s) 2013. Source

Kyle J.A.,Samford University | Brown D.A.,Palm Beach Atlantic University | Hill J.K.,Samford University
Annals of Pharmacotherapy | Year: 2013

Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of avanafil and evaluate relevant clinical trial data. Data Sources: A MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches (1966 to July 2013) were conducted using the key words: avanafil, erectile dysfunction, and phosphodiesterase type 5 (PDE5) inhibitor. Study Selection and Data Extraction: Articles evaluating avanafil for erectile dysfunction (ED) published in English and using human subjects were selected. Five clinical trials were identified. References cited in identified articles were used for additional citations. Data Synthesis: Avanafil is a highly selective PDE5 inhibitor that is a competitive antagonist of cyclic guanosine monophosphate. Specifically, avanafil has a high ratio of inhibiting PDE5 as compared with other PDE subtypes allowing for the drug to be used for ED while minimizing adverse effects. Absorption occurs quickly following oral administration with a median Tmax of 30 to 45 minutes and a terminal elimination half-life of 5 hours. Additionally, it is predominantly metabolized by cytochrome P450 3A4. As such, avanafil should not be co-administered with strong cytochrome P450 3A4 inhibitors. Dosage adjustments are not warranted based on renal function, hepatic function, age or gender. Five clinical trials suggest that avanafil 100 and 200 mg doses are effective in improving the Sexual Encounter Profile and the Erectile Function Domain scores among men as part of the International Index of Erectile Function. A network meta-analysis comparing the PDE5 inhibitors revealed avanafil was less effective on Global Assessment Questionnaire question 1 while safety data indicated no major differences among the different PDE5 inhibitors. The most common adverse effects reported from the clinical trials associated with avanafil were headache, flushing, nasal congestion, nasopharyngitis, sinusitis, and dyspepsia. Conclusions: Avanafil is a potent PDE5 inhibitor and is an effective treatment option for ED. © The Author(s) 2013. Source

Discover hidden collaborations